This study tests a new drug, nucresiran, for people with a rare heart condition called transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is when abnormal proteins build up in the heart, causing heart failure. The study compares nucresiran to a fake treatment (placebo) to see if it helps people live longer and feel better. Only people with a confirmed diagnosis of ATTR-CM and a history of heart failure can join. You must not have very severe heart failure or certain nerve problems.

• Duration: The study length and number of visits are not specified.
• Risks: Possible side effects from nucresiran are not detailed.
• Compensation: There's no mention of payment for participating.

If you have a background treatment for heart failure, you can continue it during the study. However, if you have received previous treatments that lower TTR levels, you cannot participate. This is a chance to contribute to research that might improve treatments for this serious condition.